BioCorRx Inc. (OTC: BICX), a developer and provider of innovative treatment support programs for substance use disorders and related conditions, announced on September 10, 2026, the appointment of Richard J. Baum to its Strategic Advisory Board. Baum is a former Acting Director of the White House Office of National Drug Control Policy (ONDCP) and former Executive Director of the President's Commission on Combating Drug Addiction and the Opioid Crisis. His addition to the advisory board signals a strategic push by BioCorRx to align its treatment and pharmaceutical initiatives with national drug policy priorities and to strengthen its engagement with policymakers and public health stakeholders.
Baum's credentials are substantial: during 28 years at ONDCP, he served across six presidential administrations and played a key role in developing six National Drug Control Strategies. His experience spans treatment and recovery policy, prevention, public safety, interagency coordination, and collaboration with state and local partners. He is also an Adjunct Professor at Georgetown University's McCourt School of Public Policy, author of Inside America's Opioid Crisis: 12 Hard Lessons for Today's Drug War, and a board member of United Against Fentanyl. His recent writing on the opioid crisis has appeared in The Lancet.
For BioCorRx, Baum's expertise comes at a critical time. The company is advancing two key assets: LUCEMYRA® (lofexidine), an FDA-approved non-opioid medication indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, and BICX104, an investigational biodegradable naltrexone implant technology. BICX104 is currently being evaluated in a clinical study that commenced in January 2026 (ClinicalTrials.gov Identifier: NCT07269873), supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number U01DA059994. The study is examining BICX104 alone and in combination with bupropion as a potential treatment for methamphetamine use disorder, a condition affecting approximately 2.7 million people in the United States aged 12 or older in the past year, according to the 2025 National Survey on Drug Use and Health.
Baum's appointment is significant because it bridges the gap between policy and practical treatment access. In an era of increasingly dangerous polysubstance use, particularly involving illicit fentanyl and methamphetamine, his guidance could help BioCorRx position its offerings within a comprehensive, evidence-based system of care. As Baum noted, "BioCorRx is working across several important points in the treatment continuum, including managing opioid withdrawal symptoms with LUCEMYRA. In an era of increasingly dangerous polysubstance use, particularly involving illicit fentanyl and methamphetamine, I am also encouraged by the Company's research evaluating BICX104."
Lourdes Felix, CEO of BioCorRx, emphasized that Baum's understanding of how policy translates into real-world treatment access will be invaluable as the company works to expand awareness of evidence-based approaches to addiction treatment. The appointment also reflects a broader trend of addiction treatment companies seeking to integrate policy expertise into their strategic planning, especially as federal and state governments grapple with the ongoing opioid crisis. According to the 2025 National Survey on Drug Use and Health, an estimated 4.0 million people in the United States aged 12 or older had an opioid use disorder in the past year, underscoring the urgent need for effective treatments.
BioCorRx operates through its subsidiary, BioCorRx Pharmaceuticals Inc., which focuses on pharmaceutical commercialization and development. The company's Beat Addiction Recovery program combines proprietary Cognitive Behavioral Therapy modules with peer support and medication prescribed by an independent treating physician. Its UnCraveRx® Weight Loss Program offers medication-assisted weight loss with access to concierge wellness specialists. For more information, visit www.BioCorRx.com and www.uncraverx.com.
Baum's appointment could also enhance BioCorRx's credibility with regulators and payers as it seeks to commercialize LUCEMYRA and advance BICX104. His deep understanding of the federal drug policy landscape, including the intersection of public health and public safety, may help the company navigate the complex reimbursement and regulatory environment for addiction treatments. As the opioid crisis continues to evolve, BioCorRx's ability to leverage high-level policy expertise may prove decisive in expanding access to its treatments and improving long-term recovery outcomes.
